Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Wave Life Sciences (WVE) Shares Outstanding (Weighted Average) (2016 - 2026)

Wave Life Sciences (WVE) has disclosed Shares Outstanding (Weighted Average) for 12 consecutive years, with $11.6 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 29.34% year-over-year to $11.6 million; the TTM value through Mar 2026 reached $11.6 million, up 29.34%, while the annual FY2025 figure was $168.6 million, 21.96% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $11.6 million in Q1 2026 for Wave Life Sciences, down from $168.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $168.6 million in Q4 2025 and bottomed at $7.1 million in Q2 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $68.1 million, with a median of $73.8 million recorded in 2022.
  • Year-over-year, Shares Outstanding (Weighted Average) soared 1362.84% in 2023 and then crashed 93.23% in 2025.
  • Wave Life Sciences' Shares Outstanding (Weighted Average) stood at $78.9 million in 2022, then surged by 34.55% to $106.1 million in 2023, then surged by 30.33% to $138.3 million in 2024, then increased by 21.96% to $168.6 million in 2025, then tumbled by 93.12% to $11.6 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $11.6 million, $168.6 million, and $9.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.